I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology APAO 2025
Roche and Genentech at

APAO 2025

April 03 - April 06
New Delhi, India
2025.apaophth.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Apr 7 / Roche and Genentech
Visual Acuity and Anatomic Improvements at Week 24 Maintained Through Week 72 with Faricimab▼ Treat-and-Extend Dosing for Macular Edema due to Retinal Vein Occlusion in the Phase 3 BALATON and COMINO Studies: Results and Patient Case Profiles
This presentation described that the BCVA and CST improvements and absence of macular oedema with faricimab▼ were maintained through 72 weeks and in real-world patients with RVO, with acceptable tolerability as demonstrated in the 72-week results from BALATON and COMINO trials and real-world cases.
Ophthalmology Retinal Vein Occlusion APAO-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 7 / Roche and Genentech
Key Clinical Outcomes with Faricimab▼ in Treatment-naïve Patients with Neovascular Age-Related Macular Degeneration (nAMD): Results from the TENAYA/LUCERNE Trials and Real-World FARETINA/FARWIDE Studies
This presentation described results From the TENAYA/LUCERNE Trials and Real-World FARETINA/FARWIDE Studies. Anatomic biomarkers of disease, including CST, retinal fluid and PED demonstrated greater improvement with faricimab▼ compared with aflibercept during head-to-head dosing in TENAYA/LUCERNE. Real-world results from FARETINA and FARWIDE were consistent with clinical trial results, showing vision gains, anatomical improvement and extended durability.
Ophthalmology Neovascular Age Related Macular Degeneration APAO-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 7 / Roche and Genentech
Early Fluid Resolution is Associated with Short- and Long-Term Extended Durability in Patients with Neovascular Age-Related Macular Degeneration Treated with Faricimab▼: A post hoc analysis of the TENAYA/LUCERNE Trials
This presentation summarized a post hoc analysis of the impact of maintaining extended faricimab▼ treatment intervals on visual and anatomical outcomes in the TENAYA and LUCERNE trials. Results show that faricimab▼ demonstrated greater and faster resolution of fluid vs aflibercept. The results emphasize the importance of early drying as it relates to extended durability for the patient.
Ophthalmology Neovascular Age Related Macular Degeneration APAO-2025
04:15 AM
Duration 5mins Suryamukhee Hall 401
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
Timothy Lai
Ophthalmology | Polypoidal Choroidal Vasculopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:21 AM
Duration 5mins Suryamukhee Hall 401
Port Delivery System With Ranibizumab (PDS) for Continuous Treatment in Diabetic Retinopathy (DR) Without Centre-Involved Diabetic Macular Edema (CI-DME): 2-Year Data From the Phase 3 Pavilion Trial
Timothy Lai
Ophthalmology | Diabetic Retinopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:27 AM
Duration 5mins Suryamukhee Hall 401
Response of Large or Serous Pigment Epithelial Detachment to Faricimab▼ versus Aflibercept in Patients with Neovascular Age-related Macular Degeneration: A Subgroup Analysis from TENAYA and LUCERNE
Kenneth Fong
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:39 AM
Duration 5mins Suryamukhee Hall 401
Assessment of the Clinical Effects of Anti-Ang-2 With Faricimab▼ Based on Key Outcomes From the YOSEMITE/RHINE Trials and Real-World FARETINA/FARWIDE Studies in Patients With Diabetic Macular Edema (DME)
Paisan Ruamviboonsuk
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:57 AM
Duration 5mins Suryamukhee Hall 401
Long-Term Efficacy and Safety of the Port Delivery Platform with Ranibizumab (PDS) in Patients With Neovascular Age-Related Macular Degeneration (nAMD): Ladder to Portal 5-Year Subgroup Analysis
Shih-Jen Chen
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:45 AM
Duration 5mins Suryamukhee Hall 401
Visual Acuity and Anatomic Improvements at Week 24 Maintained Through Week 72 with Faricimab▼ Treat-and-Extend Dosing for Macular Edema due to Retinal Vein Occlusion in the Phase 3 BALATON and COMINO Studies: Results and Patient Case Profiles
Anna Tan
Ophthalmology | Retinal Vein Occlusion

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:57 AM
Duration 5mins Javakusum Hall 303
Study Design and Rationale of the POYANG Study: A Phase III Randomized Clinical Trial of Faricimab▼ for Choroidal Neovascularization Secondary to Pathologic Myopia
Shih-Jen Chen
Ophthalmology | Myopic Choroidal Neovascularization

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 5mins Suryamukhee Hall 401
Faricimab▼ in Diabetic Macular Edema: Results from the RHONE-X Long-Term Extension Trial
Andrew Chang
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:03 AM
Duration 5mins Suryamukhee Hall 401
Port Delivery System With Ranibizumab (PDS) for Continuous Treatment of Diabetic Macular Edema (DME): 2-Year Data From the Phase 3 Pagoda Trial
Andrew Chang
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:09 AM
Duration 5mins Suryamukhee Hall 401
Key Clinical Outcomes with Faricimab▼ in Treatment-naïve Patients with Neovascular Age-Related Macular Degeneration (nAMD): Results from the TENAYA/LUCERNE Trials and Real-World FARETINA/FARWIDE Studies
Chaitra Jayadev
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:12 AM
Duration 5mins Suryamukhee Hall 401
Impact of Early Intraretinal Fluid Reduction on One-Year Outcomes in Diabetic Macular Edema
Gavin Tan
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:18 AM
Duration 5mins Suryamukhee Hall 401
Greater Reduction in Hard Exudates with Faricimab▼ Versus Aflibercept in Patients with Diabetic Macular Edema: Biomarker Results from the Phase 3 YOSEMITE/RHINE Trials
Gavin Tan
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:30 AM
Duration 5mins Champa Hall 304
Inhibition of Interleukin-6 Receptor (IL-6R) Signaling with Satralizumab▼ in Thyroid Eye Disease (TED): Phase 3 SatraGO-1 and SatraGO-2 Trial Design
Kelvin Chong
Ophthalmology | Thyroid eye disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:48 AM
Duration 6mins Suryamukhee Hall 401
Early Fluid Resolution is Associated with Short- and Long-Term Extended Durability in Patients with Neovascular Age-Related Macular Degeneration Treated with Faricimab▼: A post hoc analysis of the TENAYA/LUCERNE Trials
Marten Brelen
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:54 AM
Duration 5mins Suryamukhee Hall 401
Treatment Response and Safety of Faricimab▼ in Underrepresented Patients With Diabetic Macular Edema (DME): Year 1 Top-Line Results From the Phase 4 ELEVATUM Study
Shrinivas Joshi
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:17 AM
Duration 6mins Moulshree Hall 402
Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study
Jyotirmay Biswas
Ophthalmology | Uveitic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:24 AM
Duration 6mins Moulshree Hall 402
IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials
Vishali Gupta
Ophthalmology | Uveitic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.